Clinical Trial Detail

NCT ID NCT03867175
Title Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Wake Forest University Health Sciences
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.